Expired Canadian patentCanada
A method for diagnosing cancer by detecting gpc3
CA 2497418 C · Owner: Perseus Proteomics Inc. · Inventors: Ito, Yukio; Tokita, Susumu; Midorikawa, Yutaka
Overview
Drawings and full text
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Provided is a method for diagnosing cancer by detecting a novel cancer marker. Cancer can be diagnosed by detecting soluble glypican 3 in a test sample.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 4, 2003 and granted February 7, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended September 4, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 4, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
FiledSeptember 4, 2003
GrantedFebruary 7, 2012
Term endedSeptember 4, 2023
Patent numberCA 2497418 C
Classification (IPC)G01N33/57 +2 more
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.